Protalix BioTherapeutics (NYSEMKT:PLX) will host a key opinion leader (KOL) meeting on pegunigalsidase alfa, or PRX‑102, for the treatment of Fabry Disease, in New York City on December 2, at 8:00 a.m. EST.
The meeting will feature a presentation from KOL David G. Warnock, M.D., who will discuss the current treatment landscape, as well as the unmet medical need for treating Fabry patients.
The Company will also provide an update on PRX‑102.
Shares are up 8% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.